Cargando…

Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue

Factors causing the increased cardiovascular morbidity and mortality in hemodialysis (HD) patients are largely unknown. Oxylipins are a superclass of lipid mediators with potent bioactivities produced from oxygenation of polyunsaturated fatty acids. We previously assessed the impact of HD on oxylipi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tong, Dogan, Inci, Rothe, Michael, Kunz, Julius V., Knauf, Felix, Gollasch, Maik, Luft, Friedrich C., Gollasch, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781597/
https://www.ncbi.nlm.nih.gov/pubmed/35050156
http://dx.doi.org/10.3390/metabo12010034
_version_ 1784638117249024000
author Liu, Tong
Dogan, Inci
Rothe, Michael
Kunz, Julius V.
Knauf, Felix
Gollasch, Maik
Luft, Friedrich C.
Gollasch, Benjamin
author_facet Liu, Tong
Dogan, Inci
Rothe, Michael
Kunz, Julius V.
Knauf, Felix
Gollasch, Maik
Luft, Friedrich C.
Gollasch, Benjamin
author_sort Liu, Tong
collection PubMed
description Factors causing the increased cardiovascular morbidity and mortality in hemodialysis (HD) patients are largely unknown. Oxylipins are a superclass of lipid mediators with potent bioactivities produced from oxygenation of polyunsaturated fatty acids. We previously assessed the impact of HD on oxylipins in arterial blood plasma and found that HD increases several oxylipins. To study the phenomenon further, we now evaluated the differences in arterial and venous blood oxylipins from patients undergoing HD. We collected arterial and venous blood samples in upper extremities from 12 end-stage renal disease (ESRD) patients before and after HD and measured oxylipins in plasma by LC-MS/MS tandem mass spectrometry. Comparison between cytochrome P450 (CYP), lipoxygenase (LOX), and LOX/CYP ω/(ω-1)-hydroxylase metabolites levels from arterial and venous blood showed no arteriovenous differences before HD but revealed arteriovenous differences in several CYP metabolites immediately after HD. These changes were explained by metabolites in the venous blood stream of the upper limb. Decreased soluble epoxide hydrolase (sEH) activity contributed to the release and accumulation of the CYP metabolites. However, HD did not affect arteriovenous differences of the majority of LOX and LOX/CYP ω/(ω-1)-hydroxylase metabolites. The HD treatment itself causes changes in CYP epoxy metabolites that could have deleterious effects in the circulation.
format Online
Article
Text
id pubmed-8781597
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87815972022-01-22 Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue Liu, Tong Dogan, Inci Rothe, Michael Kunz, Julius V. Knauf, Felix Gollasch, Maik Luft, Friedrich C. Gollasch, Benjamin Metabolites Article Factors causing the increased cardiovascular morbidity and mortality in hemodialysis (HD) patients are largely unknown. Oxylipins are a superclass of lipid mediators with potent bioactivities produced from oxygenation of polyunsaturated fatty acids. We previously assessed the impact of HD on oxylipins in arterial blood plasma and found that HD increases several oxylipins. To study the phenomenon further, we now evaluated the differences in arterial and venous blood oxylipins from patients undergoing HD. We collected arterial and venous blood samples in upper extremities from 12 end-stage renal disease (ESRD) patients before and after HD and measured oxylipins in plasma by LC-MS/MS tandem mass spectrometry. Comparison between cytochrome P450 (CYP), lipoxygenase (LOX), and LOX/CYP ω/(ω-1)-hydroxylase metabolites levels from arterial and venous blood showed no arteriovenous differences before HD but revealed arteriovenous differences in several CYP metabolites immediately after HD. These changes were explained by metabolites in the venous blood stream of the upper limb. Decreased soluble epoxide hydrolase (sEH) activity contributed to the release and accumulation of the CYP metabolites. However, HD did not affect arteriovenous differences of the majority of LOX and LOX/CYP ω/(ω-1)-hydroxylase metabolites. The HD treatment itself causes changes in CYP epoxy metabolites that could have deleterious effects in the circulation. MDPI 2022-01-04 /pmc/articles/PMC8781597/ /pubmed/35050156 http://dx.doi.org/10.3390/metabo12010034 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Tong
Dogan, Inci
Rothe, Michael
Kunz, Julius V.
Knauf, Felix
Gollasch, Maik
Luft, Friedrich C.
Gollasch, Benjamin
Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue
title Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue
title_full Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue
title_fullStr Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue
title_full_unstemmed Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue
title_short Hemodialysis and Plasma Oxylipin Biotransformation in Peripheral Tissue
title_sort hemodialysis and plasma oxylipin biotransformation in peripheral tissue
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781597/
https://www.ncbi.nlm.nih.gov/pubmed/35050156
http://dx.doi.org/10.3390/metabo12010034
work_keys_str_mv AT liutong hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue
AT doganinci hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue
AT rothemichael hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue
AT kunzjuliusv hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue
AT knauffelix hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue
AT gollaschmaik hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue
AT luftfriedrichc hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue
AT gollaschbenjamin hemodialysisandplasmaoxylipinbiotransformationinperipheraltissue